To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial
Department of Gastroenterology and Hepatology, Linköping University Hospital School of Medicine, Linköping, Sweden.
Department of Internal Medicine, Semmelweis Egyetem, Budapest, Hungary.
First Department of Medicine, Szegedi Egyetem ÁOKI sz., Szeged, Hungary.
Medical Department I, KRH Klinikum Siloah ,Hannover, Germany.
Show others and affiliations
2021 (English)In: United European Gastroenterology journal, ISSN 2050-6406, E-ISSN 2050-6414, Vol. 9, no 7, p. 837-847Article in journal (Refereed) Published
Abstract [en]

Background and aims: Incomplete microscopic colitis (MCi) is a subtype of microscopic colitis (MC). Budesonide is recommended as a first-line treatment for MC. However, randomised trials on efficacy of treatment in MCi are missing. We therefore performed a randomised, placebo-controlled trial to evaluate budesonide as induction therapy for MCi.

Methods: Patients with active MCi were randomly assigned to either budesonide 9 mg once daily or placebo for 8 weeks in a double-blind, double-dummy design. The primary endpoint was clinical remission, defined as a mean of <3 stools/day and a mean of <1 watery stool/day in the 7 days before week 8.

Results: Due to insufficient patient recruitment, the trial was discontinued prematurely. The intention-to-treat analysis included 44 patients (21 budesonide and 23 placebo). The primary endpoint of clinical remission at week 8 was obtained by 71.4% on budesonide and 43.5% on placebo (p = 0.0582). All clinical secondary endpoints were in favour of budesonide. Budesonide decreased the number of soft or watery stools (16.3 vs. 7.7, p = 0.0186) and improved health-related quality of life for all four dimensions of the short health scale. Adverse events with a suspected relation to study drug were reported in one patient in the budesonide group and two patients in the placebo group. Neither serious nor severe adverse events occurred during the double-blind phase.

Conclusions: Budesonide decreased the frequency of soft or watery stools and improved the patients' quality of life significantly in MCi, but the primary endpoint was not met due to the low sample size (type 2 error). Budesonide was safe and well tolerated during the 8-weeks treatment course.

Place, publisher, year, edition, pages
Sage Publications, 2021. Vol. 9, no 7, p. 837-847
Keywords [en]
budesonide, drug, incomplete microscopic colitis, induction therapy, MCi, microscopic colitis, QoL, quality of life, randomised clinical trial, watery diarrhoea
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-94002DOI: 10.1002/ueg2.12131ISI: 000686519900001PubMedID: 34414678Scopus ID: 2-s2.0-85113157318OAI: oai:DiVA.org:oru-94002DiVA, id: diva2:1589992
Note

Funding Agency:

Dr Falk Pharma GmbH, Freiburg, Germany  

Available from: 2021-09-01 Created: 2021-09-01 Last updated: 2022-01-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Bohr, Johan

Search in DiVA

By author/editor
Bohr, Johan
By organisation
School of Health SciencesÖrebro University Hospital
In the same journal
United European Gastroenterology journal
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 25 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf